MLL-PTD conferred an inferior prognosis, in which the 3-year event free survival was only 10.5% (Grossmann et al., 2012), and 69% of CN-AML patients with MLL-PTD relapsed after achieving remission (Döhner et al., 2002). Here, KMT2A is linked to acute myeloid leukemia.